Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2020 | PEGASUS: pegcetacoplan for PNH

Peter Hillmen • 17 Jun 2020
EHA 2020
Non-Malignant Paroxysmal Nocturnal Hemoglobinuria Antibodies Eculizumab Pegcetacoplan
PEGASUS

Peter Hillmen, MBChB, FRCP, FRCPath, PhD, of the University of Leeds, Leeds, UK, discusses a Phase III study (NCT03500549) evaluating the efficacy and safety of pegcetacoplan, a complement 3 inhibitor, in patients with paroxysmal nocturnal hemoglobinuria (PNH). This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from Peter Hillmen

1:55
Key updates from the interim analysis of the FLAIR trial
Peter Hillmen • 10 Jun 2022
1:03
CLL trial updates from EHA 2022
Peter Hillmen • 10 Jun 2022
1:19
Acalabrutinib vs ibrutinib in previously untreated high-risk CLL
Peter Hillmen • 10 Jun 2022
1:40
The role of MRD in decision-making in CLL
Peter Hillmen • 10 Jun 2022

Related Videos

2:01
The MDT in the new era of gene therapy for hemoglobinopathies
Mattia Algeri • 15 Apr 2024
2:38
Treosulfan vs busulfan conditioning in pediatric patients with non-malignant diseases
Rita Beier • 15 Apr 2024
3:18
Immune-mediated bone marrow failure diseases & their pathophysiology: aplastic anemia, LR-MDS & PNH
Carlo Dufour • 15 Apr 2024
2:18
A global view of transfusion-dependent thalassemia: standard of care, outcomes, and unmet needs
Ali Taher • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals